Acute coronary syndromes and diabetes mellitus

Diabetes & Vascular Disease Research

Volumn 1, Issue 1, 2004, Pages 23-32

  Trichon, Benjamin H ^a   Roe, Matthew T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT;

ACUTE DISEASE; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ANTAGONISM; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; PATHOPHYSIOLOGY; REVIEW; SYNDROME; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; CORONARY DISEASE; DIABETES COMPLICATIONS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SYNDROME; THROMBOLYTIC THERAPY;

EID: 33644699986     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2004.003     Document Type: Article

References (78)

1. Garcia MJ, McNamara PM, Gordon T et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974; 23: 105–111.
2. Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997; 126: 296–306.
3. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570–2581.
4. Tschoepe D, Roesen P, Kaufmann L et al. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 1990; 20: 166–170.
5. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996; 27: 528–535.
6. Marchant B, Umachandran V, Stevenson R et al. Silent myocardial ischemia: role of subclinical neuropathy in patients with and without diabetes. J Am Coll Cardiol 1993; 22: 1433–1437.
7. Mak KH, Moliterno DJ, Granger CB et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30: 171–179.
8. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. [Erratum appears in Lancet 1994;343(8899):742.]
9. Lancet 1994; 343: 311–322.
10. Brodie BR, Stuckey TD, Wall TC et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1998; 32: 1312–1319.
11. Dracup K, Alonzo AA, Atkins JM et al. The physician's role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program. Working group on educational strategies to prevent prehospital delay in patients at high risk for acute myocardial infarction. Ann Intern Med 1997; 126: 645–651.
12. Kondo T, Kubota I, Tachibana H et al. Glibenclamide attenuates peaked T wave in early phase of myocardial ischemia. Cardiovas Res 1996; 31: 683–687.
13. Kubota I, Yamaki M, Shibata T et al. Role of ATP-sensitive K+ channel on ECG ST segment elevation during a bout of myocardial ischemia. A study on epicardial mapping in dogs. Circulation 1993; 88: 1845–1851.
14. Granger CB, Califf RM, Young S et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993; 21: 920–925.
15. The GUSTO-III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med 1997; 337: 1118–1123.
16. ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716–722.
17. The GUSTO-V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357: 1905–1914.
18. Pfeffer MA, Moye LA, Braunwald E et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA 1991; 266: 528–532.
19. Barron HV, Bowlby LJ, Breen T et al. Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Circulation 1998; 97: 1150–1156.
20. Danchin N, Vaur L, Genes N et al. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the “real world”: one-year results from a nationwide French survey. Circulation 1999; 99: 2639–2644.
21. Menown I, Patterson R, McMechan S, Hameed S, Adgey A. Use of thrombolytic therapy in females, diabetics and the elderly: trial selection – Bias or a real problem? (abstract). J Am Coll Cardiol 1999; 33: 325A.
22. Mahaffey KW, Granger CB, Toth CA et al. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30: 1606–1610.
23. Weaver WD, Simes RJ, Betriu A et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. [Erratum appears in JAMA 1998;279(23):1876.].
24. JAMA 1997; 278: 2093–2098.
25. Hasdai D, Granger CB, Srivatsa SS et al. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb angioplasty substudy Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. [Erratum appears in J Am Coll Cardiol 2000;36(2):659.].
26. J Am Coll Cardiol 2000; 35: 1502–1512.
27. Brener SJ, Ellis SG, Sapp SK et al. Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials. Am Heart J 2000; 139: 476–481.
28. Stone GW, Grines CL, Browne KF et al. Predictors of in-hospital and six-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am Coll Cardiol 1995; 25: 370–377.
29. Thomas K, Ottervanger JP, de Boer MJ et al. Primary angioplasty compared with thrombolysis in acute myocardial infarction in diabetic patients. Diabetes Care 1999; 22: 647–649.
30. Van De Werf F, Baim DS. Reperfusion for ST-segment elevation myocardial infarction: an overview of current treatment options. Circulation 2002; 105: 2813–2816.
31. Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957–966.
32. Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895–1903.
33. Silva JA, Nunez E, White CJ et al. Predictors of stent thrombosis after primary stenting for acute myocardial infarction. Cath Cardiovasc Intervent 1999; 47: 415–422.
34. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354: 708–715.
35. Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–1887.
36. Kong DF, Califf RM. Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reports. Drugs 1999; 58: 609–620.
37. Kong DF, Califf RM, Miller DP et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829–2835.
38. Theroux P, Alexander J Jr., Pharand C et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation 2000; 102: 2466–2472.
39. Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104: 2767–2771.
40. Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. [Erratum appears in Lancet 2002;359(9323):2120.].
41. Lancet 2002; 359: 189–198.
42. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. [Erratum appears in BMJ 1994;308(6943):1540.]
43. BMJ 1994; 308(6921): 81–106.
44. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329–1339.
45. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. [Erratum appears in N Engl J Med 2001;345(23):1716
46. N Engl J Med 2001;345(20):1506.
47. N Engl J Med 2001; 345: 494–502.
48. Mehta SR, Yusuf S, Peters RJ et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreat-ment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358(9281):527–533.
49. Collins R, MacMahon S, Flather M et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996; 313: 652–659.
50. Oler A, Whooley MA, Oler J et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276: 811–815.
51. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447–452.
52. Antman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593–1601.
53. Metz BK, White HD, Granger CB et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. J Am Coll Cardiol 1998; 31: 1493–1498.
54. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 1999; 353: 429–438.
55. White H, The H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358: 1855–1863.
56. Lincoff AM, Bittl JA, Harrington RA et al. REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853–863.
57. Gullestad L, Kjekshus J. [Myocardial disease in diabetes mellitus]. [Norwegian]. Tidsskrift for Den Norske Laegeforening 1992; 112: 1016–1019.
58. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. Ann Intern Med 1995; 123: 358–367.
59. Malmberg K, Herlitz J, Hjalmarson A et al. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J 1989; 10: 423–428.
60. Chen J, Marciniak TA, Radford MJ et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project. J Am Coll Cardiol 1999; 34: 1388–1394.
61. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489–497.
62. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100, 000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998; 97: 2202–2212.
63. Swedberg K, Held P, Kjekshus J et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678–684.
64. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994; 343: 1115–1122.
65. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58, 050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345: 669–685.
66. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669–677.
67. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821–828.
68. Gustafsson I, Torp-Pedersen C, Kober L et al. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J Am Coll Cardiol 1999; 34: 83–89.
69. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. [Erratum appears in Lancet 2000;356(9232):860.]
70. Lancet 2000; 355: 253–259.
71. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–1675.
72. Pfeffer MA, Swedberg K, Granger CB et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386):759–766.
73. Pfeffer MA, McMurray JJV, Velazquez EJ et al., the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906.
74. Grundy SM, Garber A, Goldberg R et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: lifestyle and medical management of risk factors. Circulation 2002; 105: e153–e158.
75. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIR-ACL study: a randomized controlled trial. JAMA 2001; 285: 1711–1718.
76. Serruys PW, Feyter P, Macaya C et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287: 3215–3222.
77. Mak KH, Topol EJ. Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus. J Am Coll Cardiol 2000; 35: 563–568.
78. Geiss LS, Herman WH, Smith PJ. National Diabetes Data Group. Diabetes in America. Bethesda, Md: National Institute of Health, National Institute of Diabetes and Kidney Diseases; 1995: 233–257.